Maria Elena Maccari

Maria Elena Maccari

Auto-generated profile, based on publicly available information

Maria Elena Maccari

https://ror.org/0245cg223Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMaria Elena Maccari
Maria Elena Maccari
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
AAAsghar Aghamohammadi
Asghar Aghamohammadi
AAAlessandro Aiuti
Alessandro Aiuti
OAOlga Aleinikova
Olga Aleinikova
SEStephan Ehl
Stephan Ehl
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2–3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

28 June 2023 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MMMaria Elena Maccari
Maria Elena Maccari
MWMartin Wolkewitz
Martin Wolkewitz
CSCharlotte Schwab
Charlotte Schwab
TLTiziana Lorenzini
Tiziana Lorenzini
JLJennifer W. Leiding
Jennifer W. Leiding
OSOksana A. Shvets
Oksana A. Shvets

10 November 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MMMaria Elena Maccari
Maria Elena Maccari
SFSebastian Fuchs
Sebastian Fuchs
PKPatrick Kury
Patrick Kury
GAGeoffroy Andrieux
Geoffroy Andrieux
SVSimon Völkl
Simon Völkl
ARAnne Rensing-Ehl
Anne Rensing-Ehl
The identification and characterization of rare immune cell populations in humans can be facilitated by their growth advantage in the context of specific genetic diseases. Here, we use autoimmune lymphoproliferative syndrome to identify a population of FAS-controlled TCRαβ+ T cells. They include CD4+, CD8+, and double-negative T cells and can be defined by a CD38+CD45RA+T-BET− expression pattern. These unconventional T cells are present in healthy individuals, are generated before birth, are enriched in lymphoid tissue, and do not expand during acute viral infection. They are characterized by a unique molecular signature that is unambiguously different from other known T cell differentiation subsets and independent of CD4 or CD8 expression. Functionally, FAS-controlled T cells represent highly proliferative, noncytotoxic T cells with an IL-10 cytokine bias. Mechanistically, regulation of this physiological population is mediated by FAS and CTLA4 signaling, and its survival is enhanced by mTOR and STAT3 signals. Genetic alterations in these pathways result in expansion of FAS-controlled T cells, which can cause significant lymphoproliferative disease.

5 January 2023 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MMMaria Elena Maccari
Maria Elena Maccari
PSPascal Schneider
Pascal Schneider
CSCristian Roberto Smulski
Cristian Roberto Smulski
AMAndrea Meinhardt
Andrea Meinhardt
FPFernando Pinto
Fernando Pinto
ARAnne Rensing-Ehl
Anne Rensing-Ehl

28 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
IHIna Harder
Ina Harder
MMMatthias Münchhalfen
Matthias Münchhalfen
GAGeoffroy Andrieux
Geoffroy Andrieux
MBMelanie Boerries
Melanie Boerries
BGBodo Grimbacher
Bodo Grimbacher
BKBaerbel Keller
Baerbel Keller
The altered wiring of signaling pathways downstream of antigen receptors of T and B cells contributes to the dysregulation of the adaptive immune system, potentially causing immunodeficiency and autoimmunity. In humans, the investigation of such complex systems benefits from nature’s experiments in patients with genetically defined primary immunodeficiencies. Disturbed B-cell receptor (BCR) signaling in a subgroup of common variable immunodeficiency (CVID) patients with immune dysregulation and expanded T-bethighCD21low B cells in peripheral blood has been previously reported. Here, we investigate PI3K signaling and its targets as crucial regulators of survival, proliferation and metabolism by intracellular flow cytometry, imaging flow cytometry and RNAseq. We observed increased basal but disturbed BCR-induced PI3K signaling, especially in T-bethighCD21low B cells from CVID patients, translating into impaired activation of crucial downstream molecules and affecting proliferation, survival and the metabolic profile. In contrast to CVID, increased basal activity of PI3K in patients with a gain-of-function mutation in PIK3CD and activated PI3K delta syndrome (APDS) did not result in impaired BCR-induced AKT-mTOR-S6 phosphorylation, highlighting that signaling defects in B cells in CVID and APDS patients are fundamentally different and that assessing responses to BCR stimulation is an appropriate confirmative diagnostic test for APDS. The active PI3K signaling in vivo may render autoreactive T-bethighCD21low B cells in CVID at the same time to be more sensitive to mTOR or PI3K inhibition.

30 April 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MEMaria Pia Esposto
Maria Pia Esposto
NMNizar Mahlaoui
Nizar Mahlaoui
HAHassan Abolhassani
Hassan Abolhassani
KAKoen Van Aerde
Koen Van Aerde
SCSimone Cesaro
Simone Cesaro
MCMatteo Chinello
Matteo Chinello
Activated phosphoinositide-3-kinase-delta (PI3Kδ) syndrome (APDS) is an autosomal dominant inborn error of immunity (IEI) characterized by combined immunodeficiency and immune dysregulation with increased risk for lymphoma and other non-lymphoid malignancies. We describe five patients with ovarian malignancies among 110 female APDS patients participating in the European Society for Immunodeficiencies (ESID) registry and identified three additional cases in the literature. These findings document a relevant predisposition to these non-hematological malignancies in APDS patients.